CHMFL-PI3KD-317 is used for studying selective PI3K delta inhibition, particularly in understanding its therapeutic potential in hematological malignancies.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.